Results 241 to 250 of about 6,578,993 (340)

Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide

Blood Cancer Journal
Diana Cirstea, Rajib Shome, Mehmet Samur, Srikanth Talluri, Joseph J. Connolly, Alexandra Jean Wright, Emilie Duvallet, Amanda N. R. Joyce, Kathleen Lively, Gina Basinsky, Andrew J. Yee, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul G. Richardson, Noopur S. Raje   +15 more
doaj   +1 more source

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Cancer Biology & Medicine
Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao, Zhen Cai   +8 more
doaj   +1 more source

Enhancing oncolytic reovirus therapy with proteasome inhibitors in multiple myeloma. [PDF]

Ann Med Surg (Lond)
Aleem MR, Baloch K, Shahid M, Talha SS.
europepmc   +1 more source

TrkA abundance is increased in cutaneous nerves in bortezomib‐induced neuropathy

Brain Pathology, EarlyView.
Cutaneous nerves in bortezomib‐induced peripheral neuropathy (BIPN) show reduced nerve fiber density, increased TrkA expression, and enhanced dermal angiogenesis, highlighting a pathological switch in NGF/TrkA signaling that may contribute to nerve damage and pain. Abstract Tropomyosin receptor kinase A (TrkA), a high‐affinity receptor for nerve growth
Yuying Jin, Nadine Cebulla, Daniel Schirmer, Eva Runau, Leon Flamm, Calvin Terhorst, Laura Jähnel, Johanna Güse, Nicola Giordani, Annett Wieser, Julian Brennecke, Annemarie Sodmann, Martin Kortüm, Robert Blum, Claudia Sommer   +14 more
wiley   +1 more source

The impact of socioeconomic status on clinical presentation of multiple myeloma. [PDF]

Hematol Transfus Cell Ther
Coelho LPS, Baptista RLR, Bretas GAB, Araujo AC, Soares AR.   +4 more
europepmc   +1 more source

Daratumumab, bortezomib and dexamethasone for previously treated myeloma—Real‐world outcomes for 2545 patients treated in England

British Journal of Haematology, EarlyView.
Sarah L. Lawton, Mark Bishton, Katherine E. Thackray, Emma Kipps, Dean Smith   +4 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Solitary Plasmacytoma and its Progression into Multiple Myeloma - A Case Report. [PDF]

J Orthop Case Rep
Mukherjee S, Senthil V.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Navigating the evolving management of smoldering multiple myeloma. [PDF]

Hemasphere
Hammami MB, Canevarolo RR, Silva AS, Alsina M, Kumar N, Baz R, Shain KH.   +6 more
europepmc   +1 more source